Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

ZOLMITRIPTAN CRS (30 MG)

ZOLMITRIPTAN CRS (30 MG)

ND

DISCOVER
DEFERIPRONE CRS (120 MG)

DEFERIPRONE CRS (120 MG)

30652-11-0

DISCOVER
MOMETASONE FUROATE FOR SYSTEMSUITABILITY CRS (10 MG)

MOMETASONE FUROATE FOR SYSTEMSUITABILITY CRS (10 MG)

NA

DISCOVER
BIOTIN FOR SYSTEM SUITABILITYCRS (10 MG)

BIOTIN FOR SYSTEM SUITABILITYCRS (10 MG)

ND

DISCOVER
FOLIC ACID FOR SYSTEM SUITABILITY CRS (10 MG)

FOLIC ACID FOR SYSTEM SUITABILITY CRS (10 MG)

NA

DISCOVER
FOLIC ACID FOR IMPURITY I IDENTIFICATION CRS (10 MG)

FOLIC ACID FOR IMPURITY I IDENTIFICATION CRS (10 MG)

293629

DISCOVER
MOMETASONE FUROATE MONOHYDRATE CRS (70 MG)

MOMETASONE FUROATE MONOHYDRATE CRS (70 MG)

ND

DISCOVER
LACOSAMIDE CRS (150 MG)

LACOSAMIDE CRS (150 MG)

175481-36-4

DISCOVER
HYOSCINE BUTYLBROMIDE FOR SYSTEM SUITABILITY CRS (15 MG)

HYOSCINE BUTYLBROMIDE FOR SYSTEM SUITABILITY CRS (15 MG)

ND

DISCOVER
CODEINE FOR SYSTEM SUITABILITY CRS - * NARC (CODEINE MONOHYD

CODEINE FOR SYSTEM SUITABILITY CRS - * NARC (CODEINE MONOHYD

NA

DISCOVER
FENTANYL CRS - * NARC (30 MG)

FENTANYL CRS - * NARC (30 MG)

ND

DISCOVER
ZOLMITRIPTAN IMPURITY A CRS (10 MG)

ZOLMITRIPTAN IMPURITY A CRS (10 MG)

ND

DISCOVER